Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, et al. Ingle JN, et al. Among authors: windschitl he. Cancer. 1991 Feb 15;67(4):886-91. doi: 10.1002/1097-0142(19910215)67:4<886::aid-cncr2820670405>3.0.co;2-o. Cancer. 1991. PMID: 1991261 Clinical Trial.
A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH Jr, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ, et al. Ingle JN, et al. Among authors: windschitl he. Cancer. 1991 Jul 1;68(1):34-9. doi: 10.1002/1097-0142(19910701)68:1<34::aid-cncr2820680107>3.0.co;2-q. Cancer. 1991. PMID: 2049750 Clinical Trial.
A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial.
Colon-Otero G, Niedringhaus RD, Hillman SH, Geyer S, Sloan J, Krook JE, Windschitl HE, Marks RS, Wiesenfeld M, Tschetter LK, Jett JJ; North Central Cancer Treatment Group. Colon-Otero G, et al. Among authors: windschitl he. Am J Clin Oncol. 2001 Dec;24(6):551-5. doi: 10.1097/00000421-200112000-00004. Am J Clin Oncol. 2001. PMID: 11801752 Clinical Trial.
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE; North Central Cancer Treatment Group. Garrity MM, et al. Among authors: windschitl he. J Clin Oncol. 2004 May 1;22(9):1572-82. doi: 10.1200/JCO.2004.10.042. J Clin Oncol. 2004. PMID: 15117979
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Laurie JA, Hahn RG, Therneau TM, Patel SR, Mailliard JA, Windschitl HE, Twito DI, Morton RF, Krook JE. Laurie JA, et al. Among authors: windschitl he. Cancer. 1992 Mar 15;69(6):1440-4. doi: 10.1002/1097-0142(19920315)69:6<1440::aid-cncr2820690622>3.0.co;2-9. Cancer. 1992. PMID: 1540881 Clinical Trial.
49 results